183 results about "Advanced glycation end-product" patented technology

Embodiments of the present invention provide an apparatus with a flexible probe suitable for determining properties of in vivo tissue from spectral information collected from various tissue sites. An illumination system provides light at a plurality of broadband ranges, which are communicated to a flexible optical probe. Light homogenizers and mode scramblers can be employed to improve the performance in some embodiments. The optical probe in some embodiments physically contacts the tissue, and in some embodiments does not physically contact the tissue. The optical probe receives light from the illumination system and transmits it to tissue, and receives light diffusely reflected in response to the broadband light, emitted from the in vivo tissue by fluorescence thereof in response to the broadband light, or a combination thereof. The optical probe can communicate the light to a spectrograph which produces a signal representative of the spectral properties of the light. An analysis system determines a property of the in vivo tissue from the spectral properties.

Embodiments of the present invention provide an apparatus suitable for determining properties of in vivo tissue from spectral information collected from the tissue. An illumination system provides light at a plurality of broadband ranges, which are communicated to an optical probe. The optical probe receives light from the illumination system and transmits it to in vivo tissue, and receives light diffusely reflected in response to the broadband light, emitted from the in vivo tissue by fluorescence thereof in response to the broadband light, or a combination thereof. The optical probe communicates the light to a spectrograph which produces a signal representative of the spectral properties of the light. An analysis system determines a property of the in vivo tissue from the spectral properties. A calibration device mounts such that it is periodically in optical communication with the optical probe.

A method of determining a measure of a tissue state (e.g., glycation end-product or disease state) in an individual. A portion of the tissue of the individual is illuminated with excitation light, then light emitted by the tissue due to fluorescence of a chemical with the tissue responsive to the excitation light is detected. The detected light can be combined with a model relating fluorescence with a measure of tissue state to determine a tissue state. The invention can comprise single wavelength excitation light, scanning of excitation light (illuminating the tissue at a plurality of wavelengths), detection at a single wavelength, scanning of detection wavelengths (detecting emitted light at a plurality of wavelengths), and combinations thereof. The invention also can comprise correction techniques that reduce determination errors due to detection of light other than that from fluorescence of a chemical in the tissue. For example, the reflectance of the tissue can lead to errors if appropriate correction is not employed. The invention can also comprise a variety of models relating fluorescence to a measure of tissue state, including a variety of methods for generating such models. Other biologic information can be used in combination with the fluorescence properties to aid in the determination of a measure of tissue state. The invention also comprises apparatuses suitable for carrying out the method, including appropriate light sources, detectors, and models (for example, implemented on computers) used to relate detected fluorescence and a measure of tissue state.

A method of determining a measure of a tissue state (e.g., glycation end-product or disease state) in an individual. A portion of the tissue of the individual is illuminated with excitation light, then light emitted by the tissue due to fluorescence of a chemical with the tissue responsive to the excitation light is detected. The detected light can be combined with a model relating fluorescence with a measure of tissue state to determine a tissue state. The invention can comprise measuring the fluorescence lifetime in either time-domain or frequency domain modes. The invention can also comprise a variety of models relating fluorescence to a measure of tissue state, including a variety of methods for generating such models. For example, multivariate models can be developed that relate lifetime trends of one or more constituents to increasing propensity to diabetes and pre-diabetes. Other biologic information can be used in combination with the fluorescence properties to aid in the determination of a measure of tissue state. The invention also comprises apparatuses suitable for carrying out the method, including appropriate light sources, detectors, and models (for example, implemented on computers) used to relate detected fluorescence and a measure of tissue state.

The present application relates to isolated proteins, particularly monoclonal antibodies, in particular CDR-grafted, humanized antibodies which bind to RAGE protein. Specifically, these antibodies have the ability to inhibit the binding of RAGE to its various ligands. The antibodies or portions thereof of described in the present application are useful for treating a disease or disorder characterized by or induced by pathophysiological ligands of RAGE, for example misfolded proteins like amyloid B and advanced glycation-end-products.

A method of determining a measure of a tissue state (e.g., glycation end-product or disease state) in an individual. A portion of the tissue of the individual is illuminated with excitation light, then light emitted by the tissue due to fluorescence of a chemical with the tissue responsive to the excitation light is detected. The detected light can be combined with a model relating fluorescence with a measure of tissue state to determine a tissue state. The invention also can comprise correction techniques that reduce determination errors due to detection of light other than that from fluorescence of a chemical in the tissue (for example, the reflectance of the tissue). Other biologic information can be used in combination with the fluorescence properties to aid in the determination of a measure of tissue state.

Fusion proteins comprising a Receptor for Advanced Glycation End Products Ligand Binding Element (RAGE-LBE) and an immunoglobulin element are disclosed. Also disclosed are fusion proteins comprising a RAGE-LBE and a dimerization domain. Also disclosed are nucleic acids encoding such fusion proteins and methods for using disclosed nucleic acids and proteins to, for example, treat RAGE-related disorders. Additional compositions and methods are also disclosed.

Novel peptides are useful as antagonists of RAGE and may be used to treat cancer, inflammation, diabetes and arthritis through the administration of a therapeutically effective amount of the peptide to a subject in need thereof.

The invention discloses an application of coumarin with a structure of formula IA or formula IB in preparing formation inhibitors of AGEs. Coumarin compounds can be used for treating and preventing various chronic diseases caused by the formation and the crosslinking of the AGEs, can also be used for preparing cosmetics with epidermis and papillary dermis anti-aging and remodeling activities and / or anti-wrinkle activities for inhibiting the formation and the crosslinking of the AGEs, and can further be used for preparing chemical agents for preventing denaturation of protein in food.

The present invention provides a method of determining disease state in an individual. A portion of the tissue of the individual is illuminated with excitation light, then light emitted by the tissue due to fluorescence of a chemical in the tissue responsive to the excitation light is detected. The HbA1c or FPG measurement of the individual (or other secondary indication of disease state) can also be determined. A model combining the tissue fluorescence and one or more of the secondary indications can be used to determine the disease state of the individual. In some embodiments, the tissue fluorescence can be used as an initial screen, and the combination with secondary indications only made for those individuals for whom the fluorescence screen indicates an increased likelihood of disease.

The invention relates to methods for identifying compounds which affect cellular stress. In particular, the method relates to identifying compounds which inhibit protein advanced glycation end product formation, where the compounds are carbonyl scavengers which inhibit the formation. The assay involves combing the substance of interest with histone H1 and ADP-ribose, and then measuring fluorescence and protein cross linking. Various inhibitors ofprotein AGE glycation have been identified, using this assay.

Various methods of administering medication(s) that inhibit the nonenzymatic formation of glycation and dehydration condensation complexes known as advanced glycation end-products (AGEs) or modulate the advanced glycation end-product receptor (RAGE) are provided. Also, a medication releasing medical devices, wherein at least a portion of the medical device releasably includes at least one of these medication(s) are provided.

Coronary artery calcification (CAC) occurs at an earlier age in diabetes and is a risk factor for coronary artery disease (CAD) in subjects with or without diabetes. One postulated mechanism for the increased CAC is the accelerated accumulation of advanced glycation end products (AGEs) in the vasculature. As certain collagen AGEs fluoresce, skin intrinsic fluorescence (SIF) can act as a novel maker of collagen AGEs levels. The present invention provides methods and apparatuses for detecting SIF that can be a useful marker of CAD risk and a therapeutic target.

The invention provides an immunological analytical method and devices for determination of the advanced glycosylation end products (AGEs), comprising a reagents for determining the AGEs, which comprises a displaying carrier suspension and the antigen or antibody immobilized on the surface of the said displaying carrier; and a test strip, comprising of: a base plate, and constitutive parts provided on the said base plate. After infusing the said reagent into the said test strip, the immunological reaction of the AGEs antigen or antibody can be determined based on the agglutination phenomenon or accompanied changes of absorbance or color and the presence or raised level of the AGEs in the diabetic patient can be known accordingly such that the practitioner can prevent the occurrence of the complications, or block further the progression of the complications at the earlier stage.

Control of blood glucose is a fundamental goal in the treatment of diabetes mellitus. Glycation of l-lysine can lower blood glucose and advanced glycation end product (AGE) free adducts can be excreted in the urine. Lysine, an inexpensive amino acid, can be administered orally or parentally, and can be incorporated into a stereocomplex matrix as a time released preparation. In patients who suffer from diabetes and concomitant renal insufficiency who cannot clear sufficient quantities of AGE free adducts enantiomeric mixtures of lysine will lower blood glucose and AGEs since d-lysine has been shown to decrease protein glycation and lower hemoglobin Alc. This invention is not intended to replace insulin or oral hypoglycemic agents but is does offer patients a low cost and probably safe complementary therapy for the treatment of diabetes mellitus. In addition to the treatment of diabetes and its complications, this invention could lower AGE burden and slow or ameliorate some of the consequences of aging.

The invention relates to a sealwort extract as well as a preparation method and a use thereof. The sealwort extract is prepared by use of a method comprising the steps of performing reduced-pressure reflux on an extract obtained by performing ethanol hot extraction on sealwort, thereby obtaining a total extract, adding distilled water to the total extract for suspending, extracting by use of isovolumetric petroleum ether, ethyl acetate and n-butyl alcohol orderly, and recovering the solvents under reduced pressure, thereby obtaining an ethyl acetate extract part; the sealwort extract has inhibition effect on AGEs (Advanced Glycation End Products), and thus can be further applied to preparing medicines for treating diabetes and complications thereof and has important clinical application value.

Provided are an AGE breakdown agent and an agent for preventing, inhibiting, or ameliorating skin deterioration stemming from AGE buildup, said agents containing, as an active ingredient, either: (i) an unsaturated fatty acid and / or a pharmaceutically-permitted salt, ester, amide, and / or glyceride thereof; or (ii) a vegetable oil (evening primrose oil, pequi oil, meadowfoam oil, shea oil, etc.) that contains an unsaturated fatty acid and / or a glyceride thereof. An agent which contains either (i) or (ii), in addition to lactic acid, glycolic acid, salicylic acid, malic acid, citric acid, phytic acid, and / or a pharmaceutically-permitted salt of one or more of said acids, is a more effective agent for preventing, inhibiting, or ameliorating skin deterioration stemming from AGE buildup.

The invention discloses a method for detecting advanced glycation end products (AGEs) in main stream smoke of a cigarette. The method specifically comprises analysis and determination of carboxy methyl lysine (CML) and carboxyethyl lysine (CEL). The method comprises the following steps: trapping total particulate matter of cigarette smoke by virtue of a Cambridge filter; carrying out ultrasonic extraction on the filter with a hydrochloric acid solution; and carrying out analysis by combining a cation exchange solid-phase extraction column purification method with liquid chromatogram-tandem mass spectrometry (LC-MS / MS). The method has the characteristics that (1) a detection method for AGEs in the main stream smoke of the cigarette is built for the first time; (2) a sample pretreatment method is built according to the characteristics of cigarette smoke sample matrix, derivative reaction is not required, and the pretreatment is simple and efficient; and (3) the method is high in sensitivity, good in qualitative accuracy and suitable for analysis of large batches of samples.

The present invention relates to advanced glycation end product (AGE) inhibitors or health functional foods for inhibiting an occurrence of diabetic complications, comprising a compound isolated from Morus Bark as active ingredients. Particularly, the present invention comprises a compound selected from the group consisting of mulberrofuran G, mulberrofuran K, kuwanon G, kuwanon Z, oxyresveratrol, 2',4',5,7-tetrahydroxyflavanone, morusignin L and dihydromorin isolated from Morus Bark. The compounds disclosed above inhibit the production of AGE which is a causative substance of diabetic complications. Thus, the compounds could be used as an AGE inhibitor and a health functional food for inhibiting diabetic nephropathy, diabetic retinopathy and diabetic neuropathy.

Disclosed is a class of compounds which inhibit the enzymatic conversion of fructose-lysine into fructose-lysine-3-phosphate in an ATP dependent reaction in a newly discovered metabolic pathway. According to the normal functioning on this pathway, fructose-lysine-3-phosphate (FL3P) is broken down to form free lysine, inorganic phosphate and 3-deoxyglucosone (3DG), the latter being a reactive protein modifying agent. 3DG can be detoxified by reduction to 3-deoxyfructose (3DF), or it can react with endogenous proteins to form advanced glycation end-product modified proteins (AGE-proteins). Also disclosed are therapeutic methods of using such inhibitors to treat glycogen storage diseases, including Fanconi's syndrome, as well as other pathological conditions resulting from the formation of AGE-proteins.

The invention discloses a detection method of a peptide-advanced glycation end product. The detection method is characterized by comprising the following steps: (1) removing a dicarbonyl compound in a liquid sample; (2) removing impurities and gathering the peptide-advanced glycation end product in the sample by using a solid-phase extraction technique; (3) determining the nature of the gathered peptide-advanced glycation end product; (4) carrying out enzymolysis on the gathered peptide-advanced glycation end product by using peptidase, removing the peptidase by using a filter membrane to obtain free peptide-advanced glycation end product; (5) quantitatively analyzing the free peptide-advanced glycation end product through mass spectrometric analysis. The method is capable of detecting the peptide-advanced glycation end product at a high flux and lowering the complexity of the quantitative detection of the peptide-advanced glycation end product; meanwhile, according to the method, the detection limit is relatively good, the linear relation between a concentration of a target product and a peak area of a signal is good, and the quantitative effect is good.

A method of determining a measure of a tissue state (e.g., glycation end-product or disease state) in an individual is disclosed. A portion of the skin of the individual is illuminated with excitation light, then light emitted by the tissue due to fluorescence of a chemical with the tissue responsive to the excitation light is detected. The detected light can be combined with a model relating fluorescence with a measure of tissue state to determine a tissue state. The invention can illuminate the skin and detect responsive light over a time that spans a plurality of cardiac cycles of the individual, which can, as an example, help mitigate the effects of time-varying signals such as those due to hemoglobin. The invention can also determine the amount of light to be directed to the skin, for example by controlling the time that a light source is energized. The amount of illumination light can be determined from a skin reflectance characteristic such as pigmentation or melanin in the skin. Controlling the amount of light directed to the tissue can reduce the dynamic range required of a corresponding optical system, for example by allowing a single system to accurately measure individuals with very light skin and individuals with very dark skin.

A method and medicament is provided for treating and inhibiting interaction of the receptor for advanced glycation end-products (RAGE) and its ligands using a natural or synthetic sulfated polysaccharide, preferably a 2-O desulfated heparin. The medicament preferably is administered intravenously, by aerosolization, intra-nasally, intra-articularly, intra-thecally, subcutaneously, topically or orally. The medicament is useful for treating a variety of conditions, including diabetes, inflammation, renal failure, aging, systemic amyloidosis, Alzheimer's disease, inflammatory arthritis, atherosclerosis, and colitis.